Core Insights - CalAmp Corp. is no longer listed on Nasdaq and will participate in the STN East Conference on March 24, 2025 [1] - The company provides advanced solutions for GPS tracking, fleet optimization, and student safety, with over 1,000 school districts in the US and Canada utilizing its technology [2] - CalAmp aims to empower school districts with real-time data to enhance fleet efficiency and student safety [3] Company Overview - CalAmp offers flexible solutions for monitoring, tracking, and protecting vital assets, with over 10 million active edge devices and more than 220 approved or pending patents [5] - The company is recognized as a leader in telematics, providing innovative and dependable solutions for commercial and government organizations [5] Event Participation - At the STN East Conference, CalAmp Synovia will engage with transportation professionals to discuss industry trends and innovations [3] - Attendees at Booth 108 will have the opportunity to interact with CalAmp experts for insights into future student transportation technology [2][3]

Group 1 - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression and restore healthy protein levels [1][4] - The company will participate in several upcoming investor conferences, including Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 12, 2025, and the Leerink Partners Global Healthcare Conference on March 10, 2025 [1][2] - CAMP4's proprietary RAP Platform™ allows for the mapping of regRNAs and the generation of therapeutic candidates aimed at treating over 1,200 genetic disorders where a modest increase in protein expression could be clinically meaningful [4] Group 2 - The company is developing disease-modifying treatments for a wide range of rare and prevalent genetic diseases, emphasizing the importance of increasing healthy protein levels for therapeutic benefits [4] - The upcoming presentations will be accessible via webcasts, with replays available for 30 days following the events [3]

Core Insights - CalAmp has integrated Okta Single Sign-On (SSO) into its iOn™ Fleet and Device Management applications, enhancing security and simplifying user access management [1][2] - The partnership with Okta aims to provide customers with improved security and efficient access management across CalAmp applications [2] Product Features - Users can log in once to access all CalAmp applications, reducing password fatigue and enhancing security with a single login [6] - Multi-Factor Authentication (MFA) via Okta adds an extra layer of protection against unauthorized access [6] - IT teams can manage and revoke user access from a single platform, improving operational efficiency and control [6] - Organizations can customize security policies for SSO enforcement to meet specific needs [6] - Role-Based Access Control (RBAC) allows management of user permissions across iOn™ and Device Management, ensuring appropriate access to tools and data [6] Company Overview - CalAmp provides telematics and connected intelligence solutions, helping organizations monitor, track, and protect vital assets [3] - The company has over 10 million active edge devices and holds 220+ approved or pending patents, positioning itself as a leader in the telematics industry [3]

Company Overview - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression and restore healthy protein levels [1][3] - The company is working on disease-modifying treatments for a wide range of rare and prevalent genetic diseases, where increasing healthy protein levels may provide significant therapeutic benefits [3] Upcoming Event - Josh Mandel-Brehm, President & CEO of CAMP4, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 3:45 p.m. PST [1] - The event will be available for live webcast on CAMP4's investor relations page, with a replay archived for 30 days post-conference [2] Technology and Approach - CAMP4's proprietary RAP Platform™ enables the mapping of regRNAs and the generation of therapeutic candidates aimed at targeting regRNAs associated with genes involved in haploinsufficient and recessive partial loss-of-function disorders [3] - There are over 1,200 disorders where a modest increase in protein expression could have clinically meaningful effects [3]

Core Insights - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to enhance gene expression and restore healthy protein levels [1][2] 2024 Key Highlights - 2024 was a transformative year for CAMP4, marked by a successful IPO, with gross proceeds of approximately $75.0 million from the sale of 6,820,000 shares at an initial price of $11.00 per share [5] - The company received Rare Pediatric Disease Designation and Orphan Drug Designation for its lead program CMP-CPS-001, aimed at treating urea cycle disorders (UCDs) [4][5] - The Phase 1 study of CMP-CPS-001 demonstrated favorable safety results, with all treatment emergent adverse events being Grade 1 (mild) or Grade 2 (moderate) [5] - CAMP4 was added to the Russell 2000® Index, enhancing its market visibility [4][9] - A new discovery program targeting a GBA1 regRNA for Parkinson's disease was initiated [4][9] Expected Milestones in 2025 - The company anticipates reporting Multiple Ascending Dose (MAD) safety and key biomarker data in the second half of 2025, which could facilitate the advancement of CMP-CPS-001 into a registrational Phase 2/3 trial in 2026 [2][4][9] - Initiation of GLP toxicity studies for the lead ASO candidate targeting neurodevelopmental disorders caused by SYNGAP1 mutations is planned for this year [9] - CAMP4 aims to expand its strategic partnerships to maximize the value of its RAP platform [9]

Core Viewpoint - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting therapeutics aimed at restoring healthy protein levels in various genetic diseases [1]. Group 1: Conference Participation - CAMP4 will present and hold one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference from December 3rd to 5th, 2024 [1]. - The presentation is scheduled for December 5, 2024, from 1:00 to 1:25 PM ET, and a live webcast will be available on the company's investor relations website [2]. Group 2: Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases by amplifying healthy protein levels through its proprietary RAP Platform™, which targets regRNAs that regulate gene expression [4]. - The company's approach involves using ASO drug candidates to amplify mRNA, which may provide therapeutic benefits in conditions characterized by haploinsufficiency and recessive partial loss-of-function disorders [4].

Core Insights - CAMP4 Therapeutics Corporation successfully completed its Initial Public Offering (IPO), raising gross proceeds of $82.1 million, which positions the company for continued growth and development of its programs [1][3][4] - The company has made significant progress in its lead program, CMP-CPS-001, which has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, indicating its potential as a novel therapeutic for urea cycle disorders [2][3] - CAMP4 has entered a strategic research collaboration with BioMarin, valued at over $370 million, to leverage its RNA Actuating Platform for identifying therapeutics targeting regRNAs associated with genetic diseases [1][2][3] Financial Performance - For the third quarter of 2024, CAMP4 reported a net loss of $13.5 million, compared to a net loss of $11.7 million for the same period in 2023 [7][12] - Research and Development (R&D) expenses were $9.7 million for Q3 2024, slightly down from $9.8 million in Q3 2023, primarily due to a reduction in workforce-related expenses [5] - General and Administrative (G&A) expenses increased to $3.8 million in Q3 2024 from $2.9 million in Q3 2023, mainly due to higher stock-based compensation and patent-related expenses [6] Clinical Development - The Phase 1 clinical trial of CMP-CPS-001 has completed dosing for all Single Ascending Dose (SAD) cohorts, with safety data expected to be reported in Q1 2025 [1][3] - Following the SAD data, the company anticipates reporting Multiple Ascending Dose (MAD) biomarker efficacy data in the second half of 2025, which may enable a registrational Phase 2/3 study [2][3] Cash Position - As of September 30, 2024, CAMP4 had $2.5 million in cash and cash equivalents, but on a pro forma basis, considering the IPO proceeds, the company is well-positioned for future growth [4][12]

Group 1 - CAMP4 Therapeutics Corporation priced its initial public offering of 6.82 million shares at $11.00 per share, raising approximately $75 million in gross proceeds [1] - The company is focused on RNA therapeutics for rare diseases and has initiated a Phase 1 study for CMP-CPS-001 targeting urea cycle disorders [1] - CMP-CPS-001 has received FDA Orphan Drug and Rare Pediatric Disease Designations [1] Group 2 - CAMP4 announced a research collaboration with BioMarin Pharmaceutical Inc to develop therapeutics that target regulatory RNA sequences [2] - BioMarin has the right to select two targets from CAMP4's RAP Platform for clinical development [2] Group 3 - William Blair initiated coverage on CAMP4, highlighting its lower market cap compared to other early-stage genetic medicine companies despite its innovative RAP platform [3] - Piper Sandler also initiated coverage, suggesting that regulatory RNAs could represent a significant advancement over traditional therapies [3] Group 4 - Piper's analysis indicates that an increase in ureagenesis rate test (URT) would signal the effectiveness of CMP-CPS-001 in lowering ammonia levels [4] - The analyst anticipates registrational Phase 2 studies for urea cycle disorders and potential FDA approval by 2029, with projected peak revenues of $1.0 billion by 2036 [4] - Piper has set an Overweight rating for CAMP4 with a price target of $18 [4] Group 5 - CAMP stock has increased by 13.5%, trading at $9.33 [5]

Company Overview - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regulatory RNA-targeting therapeutics aimed at restoring healthy protein levels for various genetic diseases [5] - The company utilizes its proprietary RAP Platform™ to map regulatory RNAs and create therapeutic candidates targeting genes associated with over 1,200 disorders [5] Initial Public Offering (IPO) Details - CAMP4 announced the pricing of its IPO, offering 6,820,000 shares at $11.00 per share, with expected gross proceeds of approximately $75.0 million before expenses [1] - The common stock is set to begin trading on the Nasdaq Global Market under the ticker symbol "CAMP" on October 11, 2024, with the offering expected to close on October 15, 2024, subject to customary conditions [1] - Underwriters have a 30-day option to purchase an additional 1,023,000 shares at the IPO price [1] Underwriters - J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are acting as joint book-running managers for the offering [2]

Group 1 - The article discusses the services provided by IPO Edge, which includes actionable information on growth stocks through first-look S-1 filings, previews on upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a comprehensive guide to IPO investing [1]